Isatuximab During Stem Cell Transplant

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

What's the purpose of the trial?

The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. 

Trial status

Accepting patients

Phase
Phase 2
Enrollment
39
Last Updated
2 months ago
Patient Screener

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Isatuximab is a type of drug called a monoclonal antibody. Isatuximab targets a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Isatuximab

Accepting patients

Standard Care

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.